Programming Note: Cost Curve is probably off tomorrow, almost certainly off Friday, and definity off Monday. I’ll catch everyone up next week. J.P. Morgan put, arguably, the two hottest companies
It’s been a slow week, so it’s probably useful for me to pause for a moment and think about what’s coming. Here’s a short list of the milestones that I’m
Pretty much every page of the new IQVIA “Global Trends in R&D 2024” report is worth deep consideration. It is the definitive atlas of how and where biopharma is investing